The board of AstraZeneca rejected the improved $119 billion takeover offer from U.S. drugmaker Pfizer, a decision that has led to a slide in the U.K. company's share price. In a statement Monday, AstraZeneca's board said it "reiterates its confidence in AstraZeneca's ability to deliver on its prospects as an independent, science led business." Read the full story
This story made our list of "Top Industry ShakeUps (and Shakedowns) from 2014." See the full list.